MZ-101

MZ-101 (GYS1-IN-2) is an orally active, potent and selective small-molecule glycogen synthase 1 (GYS1) inhibitor with with an IC50 value of 0.041 µM. MZ-101 reduces glycogen concentrations in cells and in mice. MZ-101 can used to study GYS1 -mediated Pompe disease and other glycogen storage diseases[1][2][3].

Product Specifications

CAS Number

[2839908-40-4]

Product Name Alternative

GYS1-IN-2

UNSPSC

12352005

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/mz-101.html

Purity

98.98

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C([C@H]1N(C[C@@H](C1)F)C(CC2=CN=NN2)=O)N[C@@H](C3=CC=CC=C3)C4=CC=C(C=C4)C(C)C

Molecular Formula

C25H28FN5O2

Molecular Weight

449.52

References & Citations

[1]David John Morgans, et al. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof. WO2022198196. 2022-09-22.|[2]Ullman JC, et al. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. Sci Transl Med. 2024 Jan 17;16 (730) :eadf1691.|[3]Gaspar RC, et al. Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease. Am J Physiol Endocrinol Metab. 2024 Oct 1;327 (4) :E524-E532.